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ype 1 diabetes is characterized by T-cell–medi-
ated destruction of insulin-producing -cells.
Progression of -cell autoimmunity is simplisti-
cally viewed as a functional imbalance favoring
the development of -cell–speciﬁc pathogenic type 1 ver-
sus immunoregulatory T-cells (Tregs) (1,2). The latter
consist of a number of distinct subsets with varying
functions that can prevent differentiation or function of
type 1 T-cells (3). It is unclear how this functional balance
between pathogenic T-cells and Tregs goes awry, leading
to massive -cell destruction, or is maintained in at-risk
individuals who remain diabetes free. In this issue of
Diabetes, Peakman and colleagues (4) investigate den-
dritic cells in diabetic patients and provide suggestive
evidence for a new player in regulating -cell–speciﬁc
T-cell reactivity.
Dendritic cells are a heterogeneous group of innate
effectors that serve two general functions in controlling
T-cell immunity. The ﬁrst is to process and present anti-
gens to T-cells, which is essential for T-cell activation and
expansion. Second, dendritic cells secrete cytokines that
condition the extracellular milieu and determine the na-
ture of the T-cell response. Although much attention has
been focused on the capacity of dendritic cells to initiate
proinﬂammatory responses to microbial pathogens, it is
clear that dendritic cells serve an important role in estab-
lishing and maintaining tolerance to self-antigens (5).
These opposing functions are governed by the maturation
status and types of cytokines secreted by dendritic cells
(6). For instance, infectious microbes in contact with
immature dendritic cells promote maturation, which is
characterized by the following: 1) an increased capacity to
present antigens and stimulate T-cells and 2) secretion of
proinﬂammatory cytokines, which promote differentiation
of type 1 T-cells that efﬁciently clear the infectious agent
(6). Depending on the type of dendritic cell, different
cytokines are secreted to establish a proinﬂammatory
milieu. Mature myeloid dendritic cells (mDCs) secrete
interleukin (IL)-12, which directly induces differentiation
of type 1 T-cells (6). Plasmacytoid dendritic cells (pDCs),
the focus of the Peakman group’s study, secrete interferon
(IFN)-, which is well known for its potent antiviral
properties (7).
Self-tolerance is mediated by the dendritic cell via
passive and active processes. Under noninﬂammatory or
homeostatic conditions, the majority of dendritic cells are
found in an immature state. Immature dendritic cells
presenting self-antigens fail to both stimulate T-cells and
secrete cytokines (8). Under certain conditions, immature
dendritic cells presenting self-antigens can be tolergenic
by inducing either a state of unresponsiveness or apopto-
sis in the autoreactive T-cells (9). In addition, immature
dendritic cells stimulated by apoptotic bodies or cytokines
such as transforming growth factor- and IL-10 develop a
tolergenic phenotype upon subsequent maturation, char-
acterized by the secretion of anti-inﬂammatory cytokines
or a capacity to preferentially expand Treg (9).
In view of their pivotal role regulating T-cell immunity,
dendritic cells would be expected to impact the functional
balance between pathogenic T-cells and Tregs in type 1
diabetes. Indeed, studies in the nonobese diabetic (NOD)
mouse, a spontaneous model of type 1 diabetes, have
shown that mDCs exhibit a hyperinﬂammatory phenotype.
Namely, NOD dendritic cells have an elevated capacity to
stimulate T-cells and secrete proinﬂammatory cytokines
such as IL-12 (10,11). This dendritic cell phenotype would
be expected to directly drive differentiation of pathogenic
type 1 T-cells and promote -cell destruction. Studies in
diabetic patients, however, suggest a different scenario.
Monocyte-derived dendritic cells from peripheral blood of
diabetic patients exhibit a limited T-cell stimulatory capac-
ity relative to at-risk or healthy individuals (12,13). Accord-
ingly, it has been proposed that these “immature-like”
dendritic cells are less effective at stimulating Tregs,
which in turn would be predicted to indirectly favor
differentiation and expansion of pathogenic type 1 T-cells
(12,13).
Whereas most studies to date have investigated mDCs in
diabetic individuals, the report by Peakman and col-
leagues focuses on pDCs. pDCs are of particular interest in
view of studies linking this dendritic cell subset with other
types of autoimmunity, most notably systemic lupus ery-
thematosus (SLE). Patients with SLE exhibit elevated
levels of serum IFN-, which activates several pathways
that promote inﬂammation (e.g., autoimmunity) (14). In-
terestingly, pDC activation and IFN- secretion are attrib-
uted to binding of immune complexes consisting of
autoantibodies and nucleic acids (15). These immune
complexes are bound and internalized by the FcRIIA
receptor expressed by pDC. The nucleic acid moieties are
then recognized by Toll-like receptors residing in the
cytoplasm of pDCs, which initiate a cascade of signaling
events that lead to the production of copious amounts of
IFN- (16). The role of pDCs in antigen presentation to
autoreactive T-cells, however, is ill deﬁned in SLE.
Peakman and colleagues compared the frequency of
pDCs and subsets of mDCs in peripheral blood of patients
with recent-onset diabetes, patients with long-standing
diabetes, and matching healthy control subjects. A modest
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12 DIABETES, VOL. 58, JANUARY 2009but signiﬁcant increase in the frequency of pDCs and a
concomitant decrease in mDCs in patients with recent-
onset diabetes versus control subjects was found. Impor-
tantly, the indirect effects of hyperglycemia on dendritic
cells were ruled out by demonstration that the frequency
of pDCs and mDCs in type 2 diabetic patients was un-
changed compared with that in healthy control subjects.
Interestingly, long-standing diabetic patients exhibited a
normal frequency of pDCs (and mDCs), and a similar trend
was detected in a small number of patients monitored over
a 2-year period, beginning at the time of diabetes onset.
Therefore, the increase in pDCs appears to be selective for
the onset of diabetes. Furthermore, pDCs in patients with
recent-onset diabetes exhibited an immature or resting
phenotype, consistent with the observation that serum
levels of IFN- were normal in these patients. Therefore,
unlike SLE, in which activated pDCs are believed to drive
autoimmunity via IFN- secretion, pDCs may serve a
distinct role in type 1 diabetes independent of cytokine
secretion.
A clue to the role pDC may have in the diabetogenic
response came from experiments assessing the T-cell
stimulatory capacity of pDCs. The latter was tested em-
ploying a clever in vitro assay system that exploited the
use of a recombinant insulinoma-associated protein 2
(IA2) molecule, containing an inﬂuenza hemagglutinin
peptide, and sera from diabetic patients, containing anti-
IA2–speciﬁc autoantibodies. pDCs were found to stimulate
a hemagglutinin-speciﬁc T-cell clone after incubation with
immune complexes of the IA2-hemagglutinin fusion mole-
cule and serum anti-IA2 autoantibodies. Importantly, efﬁ-
cacy of T-cell stimulation by pDCs, but not mDCs, was
dependent on the concentration of serum anti-IA2 autoan-
tibody. These results suggest that at least one role for the
pDC in type 1 diabetes is to present -cell–autoantigen–
autoantibody complexes to the corresponding autoreac-
tive T-cells.
This study raises a number of interesting questions for
future work. First and foremost, what is the outcome of
autoantigen presentation by pDCs to T-cells? For instance,
do pDCs preferentially induce type 1 versus Treg re-
sponses? The latter possibility is suggested by the fact
that, in diabetic individuals, pDCs exhibit an immature
status consistent with a tolergenic phenotype. However,
whether pDCs residing in the draining pancreatic lymph
nodes or inﬁltrating the islets have a similar phenotype is
obviously not known. It is noteworthy that a recent study
by Katz and colleagues (16) demonstrated that pDCs have
a protective function in NOD mice. A related question
deals with the relevance of the elevated frequency of pDCs
in peripheral blood at the onset of diabetes. Accordingly, it
will be important to determine whether the increase in
pDCs parallels the appearance of islet-speciﬁc autoanti-
bodies in at-risk individuals and whether pDCs are bound
by immune complexes. In conclusion, the study by Peak-
man and colleagues provides a key starting point to study
pDCs and their potential role in regulating -cell–speciﬁc
T-cell responses.
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